Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT…

By Dr. Matthew Watson

LA JOLLA, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that interim data from the Phase 1b/2 EQUATE study of itolizumab in acute graft-versus-host disease (aGVHD) has been accepted as a late-breaking oral presentation at the 2021 TCT Meetings Digital Experience, being held February 8-12, 2021.

Read the original here:
Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT...

Related Post


categoriaGlobal News Feed commentoComments Off on Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT… | dataJanuary 22nd, 2021

About...

This author published 3712 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research